Pfizer Inc. $PFE Shares Sold by Beverly Hills Private Wealth LLC

Beverly Hills Private Wealth LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.9% during the 2nd quarter, Holdings Channel.com reports. The fund owned 27,534 shares of the biopharmaceutical company’s stock after selling 829 shares during the period. Beverly Hills Private Wealth LLC’s holdings in Pfizer were worth $667,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Mountain Capital Investment Advisors Inc. acquired a new stake in Pfizer during the second quarter worth about $200,000. Community Bank of Raymore raised its stake in Pfizer by 20.9% during the second quarter. Community Bank of Raymore now owns 49,130 shares of the biopharmaceutical company’s stock worth $1,191,000 after acquiring an additional 8,500 shares during the period. Cidel Asset Management Inc. raised its stake in Pfizer by 3.2% during the second quarter. Cidel Asset Management Inc. now owns 76,777 shares of the biopharmaceutical company’s stock worth $1,861,000 after acquiring an additional 2,373 shares during the period. Chicago Partners Investment Group LLC raised its stake in Pfizer by 6.1% during the second quarter. Chicago Partners Investment Group LLC now owns 77,570 shares of the biopharmaceutical company’s stock worth $1,967,000 after acquiring an additional 4,462 shares during the period. Finally, First Bancorp Inc ME raised its stake in Pfizer by 6.7% during the second quarter. First Bancorp Inc ME now owns 18,215 shares of the biopharmaceutical company’s stock worth $442,000 after acquiring an additional 1,145 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.7%

Pfizer stock opened at $24.68 on Tuesday. The firm has a 50 day simple moving average of $24.89 and a 200-day simple moving average of $24.12. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a market capitalization of $140.33 billion, a PE ratio of 13.13, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.22.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Analysts Set New Price Targets

PFE has been the topic of several research reports. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, UBS Group restated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.